Manuel Castillejos1, Carlos Cabello-Gutiérrez2, José Alberto Choreño-Parra3, Víctor Hernández2, Javier Romo1, Fernando Hernández-Sánchez2, Dina Martínez1, Andrés Hernández1, Luis Jiménez-Álvarez4, Carmen M Hernández-Cardenas5, Eduardo Becerril-Vargas1, José A Martínez-Orozco1, José Luis Sandoval-Gutiérrez1, Cristóbal Guadarrama1, Enrique Olvera-Masetto1, Leticia Alfaro-Ramos1, Alfredo Cruz-Lagunas4, Gustavo Ramírez4, Eduardo Márquez4, Lisa Pimentel6, Nora E Regino-Zamarripa7, Criselda Mendoza-Milla4, Aminadab Goodina6, Erika Hernández-Montiel6, Rodrigo Barquera8, Alfredo Santibañez9, Guillermo Domínguez-Cherit10, Rogelio Pérez-Padilla1, Justino Regalado11, Patricio Santillán-Doherty11, Jorge Salas-Hernández12, Joaquín Zúñiga13. 1. Institutional Influenza Committee, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico. 2. Department of Research in Virology and Mycology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico. 3. Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico; Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico. 4. Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico. 5. Institutional Influenza Committee, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico; Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City, Mexico. 6. Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico; Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City, Mexico. 7. Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico; Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico; Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City, Mexico. 8. Laboratory of Archeogenomics, Max Planck Institute, Gena, Germany. 9. Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico; Laboratory of Archeogenomics, Max Planck Institute, Gena, Germany. 10. Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City, Mexico; Critical Care Unit, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. 11. Institutional Influenza Committee, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico; Dirección Médica, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico. 12. Institutional Influenza Committee, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico; Dirección General, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico. Electronic address: joazu@tec.mx. 13. Institutional Influenza Committee, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico; Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico; Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City, Mexico. Electronic address: jorgesalash@yahoo.com.
Abstract
OBJECTIVES: To evaluate the performance of rapid influenza diagnostic tests (RIDT) and influenza vaccines' effectiveness (VE) during an outbreak setting. METHODS: We compared the performance of a RIDT with RT-PCR for influenza virus detection in influenza-like illness (ILI) patients enrolled during the 2016/17 season in Mexico City. Using the test-negative design, we estimated influenza VE in all participants and stratified by age, virus subtype, and vaccine type (trivalent vs quadrivalent inactivated vaccines). The protective value of some clinical variables was evaluated by regression analyses. RESULTS: We enrolled 592 patients. RT-PCR detected 93 cases of influenza A(H1N1)pdm09, 55 of AH3N2, 141 of B, and 13 A/B virus infections. RIDT showed 90.7% sensitivity and 95.7% specificity for influenza A virus detection, and 91.5% sensitivity and 95.3% specificity for influenza B virus detection. Overall VE was 33.2% (95% CI: 3.0-54.0; p = 0.02) against any laboratory-confirmed influenza infection. VE estimates against influenza B were higher for the quadrivalent vaccine. Immunization and occupational exposure were protective factors against influenza. CONCLUSIONS: The RIDT was useful to detect influenza cases during an outbreak setting. Effectiveness of 2016/17 influenza vaccines administered in Mexico was low but significant. Our data should be considered for future local epidemiological policies.
OBJECTIVES: To evaluate the performance of rapid influenza diagnostic tests (RIDT) and influenza vaccines' effectiveness (VE) during an outbreak setting. METHODS: We compared the performance of a RIDT with RT-PCR for influenza virus detection in influenza-like illness (ILI) patients enrolled during the 2016/17 season in Mexico City. Using the test-negative design, we estimated influenza VE in all participants and stratified by age, virus subtype, and vaccine type (trivalent vs quadrivalent inactivated vaccines). The protective value of some clinical variables was evaluated by regression analyses. RESULTS: We enrolled 592 patients. RT-PCR detected 93 cases of influenza A(H1N1)pdm09, 55 of AH3N2, 141 of B, and 13 A/B virus infections. RIDT showed 90.7% sensitivity and 95.7% specificity for influenza A virus detection, and 91.5% sensitivity and 95.3% specificity for influenza B virus detection. Overall VE was 33.2% (95% CI: 3.0-54.0; p = 0.02) against any laboratory-confirmed influenza infection. VE estimates against influenza B were higher for the quadrivalent vaccine. Immunization and occupational exposure were protective factors against influenza. CONCLUSIONS: The RIDT was useful to detect influenza cases during an outbreak setting. Effectiveness of 2016/17 influenza vaccines administered in Mexico was low but significant. Our data should be considered for future local epidemiological policies.
Authors: Jose Alberto Choreño-Parra; Luis Armando Jiménez-Álvarez; Gustavo Ramírez-Martínez; Montserrat Sandoval-Vega; Citlaltepetl Salinas-Lara; Carlos Sánchez-Garibay; Cesar Luna-Rivero; Erika Mariana Hernández-Montiel; Luis Alejandro Fernández-López; María Fernanda Cabrera-Cornejo; Eduardo Misael Choreño-Parra; Alfredo Cruz-Lagunas; Andrea Domínguez; Eduardo Márquez-García; Carlos Cabello-Gutiérrez; Francina Valezka Bolaños-Morales; Lourdes Mena-Hernández; Diego Delgado-Zaldivar; Daniel Rebolledo-García; Parménides Guadarrama-Ortiz; Nora E Regino-Zamarripa; Criselda Mendoza-Milla; Ethel A García-Latorre; Tatiana Sofia Rodiguez-Reyna; Diana Cervántes-Rosete; Carmen M Hernández-Cárdenas; Shabaana A Khader; Albert Zlotnik; Joaquín Zúñiga Journal: Front Immunol Date: 2021-02-26 Impact factor: 7.561
Authors: Ji Young Lee; Seung Hwan Baek; Jong Gyun Ahn; Seo Hee Yoon; Moon Kyu Kim; Soo Yeon Kim; Kyung Won Kim; Myung Hyun Sohn; Ji-Man Kang Journal: J Korean Med Sci Date: 2022-01-03 Impact factor: 2.153